J&J, Idor­sia build out piv­otal dataset for their $230M hy­per­ten­sion drug, show­ing a main­tained re­sponse

J&J and Idor­sia pre­sent­ed new Phase III da­ta for their hy­per­ten­sion drug Tues­day morn­ing.

The tri­al found that aproci­ten­tan, the drug in ques­tion, re­duced blood …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER